Search for: "Amgen Inc. v. Sanofi"
Results 81 - 100
of 103
Sort by Relevance
|
Sort by Date
1 Mar 2014, 8:55 pm
In support thereof, Sanofi directed the Court’s attention to Amgen v. [read post]
13 Nov 2013, 8:40 pm
In Enzo Biochem, Inc. v. [read post]
2 Dec 2011, 2:00 pm
Amgen, Inc., ___ F. [read post]
7 Sep 2010, 6:10 pm
Highlights this week included: CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector) Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor) Aranesp (Darbepoetin) – EU: ECJ says ‘no’ to Kirin Amgen,… [read post]
31 Aug 2010, 10:01 pm
Apotex Inc. et al (Docket Report) Lovenox (Enoxaparin) – US: DC District Court denies preliminary injunction in generic Lovenox case; Is the juice worth the squeeze for Sanofi to appeal? [read post]
18 Mar 2010, 2:30 am
Amgen, Inc. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
9 Dec 2009, 3:59 pm
Amgen Inc. [read post]
1 Dec 2009, 9:45 am
Amgen Inc. and Wyeth (patent infringement) 10/28: Deston Therapeutics LLC, Unigen Pharmaceuticals Inc. v. [read post]
12 Dec 2008, 8:42 am
See Amgen Inc. v. [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ… [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge), (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
20 Jun 2008, 8:07 am
: (IP finance), Technical assistance a key point of discussion at TRIPS Council: (Intellectual Property Watch), WIPO turmoil as new DG’s future comes under threat: (IAM), WIPO to host inter-regional forum to explore strategies to enhance development and service-orientation of IP offices: (WIPO), Controversy over lack of transparency and overreaching enforcement provisions in ACTA: (Spicy IP), (Spicy IP) Global - Trade Marks / Domain Names / Brands World anti-counterfeiting day:… [read post]
11 Apr 2008, 9:00 am
No problem…: Lundbeck A/S v Generics UK Ltd & Ors: (IPKat), Exelon (Rivastigmine Tartrate) – Dr Reddy’s and Novartis settle Exelon patent dispute: (Therapeutics Daily), GeneMaker – Codon Devices, Blue Heron Biotechnology settle patent suit over gene synthesis platform: (Patent Docs), Glucophage (Metformin) – Depomed settles patent litigation against IVAX: (SmartBrief), (IP Law360), (GenericsWeb), Lexapro… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
